Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. - Wikidata - awgldk - TriplyDB

Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children.

Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children.

http://www.wikidata.org/entity/Q44343579

about

Innovative clinical trial design for pediatric therapeutics Getting to 90-90-90 in paediatric HIV: What is needed?Population pharmacokinetics of abacavir in pregnant women.Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour?Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2)Population pharmacokinetic studies in pediatrics: issues in design and analysis.The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected children High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults.A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV.Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.Optimising the management of fever and pain in children.Liquid chromatography-mass spectrometry methods for the intracellular determination of drugs and their metabolites: a focus on antiviral drugs.A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.Role of ABCB1, ABCG2, ABCC2 and ABCC5 transporters in placental passage of zidovudine.

P2860

Q24635308-F9AD2EB8-F6CA-4535-B3EE-B8695D68552A Q30385352-CA1ED631-46EC-428A-88CE-1EE94DD95E09 Q34299084-95DF5AFD-554E-4139-8613-DBD0B68E99C5 Q34635561-26C966D3-BE8F-4C30-9941-2449E3C52A5F Q35005051-51F80850-FFB1-48EA-BADA-105A332CFDEE Q36341632-F26E5797-4B67-4A2C-A76E-45E05C00F10F Q36349683-76A145D3-4AB7-4863-B6D2-6A84D112C83E Q36744874-218D51EA-0FC4-48DC-96D5-CEE4C4E4D598 Q37263890-022B214A-F0C6-4F19-9CB4-1047FDCE94CB Q37492046-40C26D1B-B832-4D59-830E-83522191D20E Q37588728-60743996-3C88-4207-80BC-6DB6D13D3ABD Q37708677-300E914E-59CE-461F-962A-5A4E940C4F54 Q37835819-C789C1CB-0C55-436D-A138-B68204FAEC0B Q37866289-489ED3CF-4533-4B5F-8C6E-78EF500B0F98 Q38060826-ACA16627-862F-405D-AB7E-348760CF64A0 Q39434360-0B8AA982-DAE3-4B01-B653-50CEDA7BC3A8 Q48072950-AC834E10-342C-41EF-9B35-522582975943 Q53816970-CA8F0304-5611-4635-ABE6-4E5E9A0B902C

P2860

Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children.

http://www.wikidata.org/entity/Q44343579

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Population pharmacokinetics an ...... infected infants and children.

@en

Population pharmacokinetics an ...... infected infants and children.

@nl

type

label

Population pharmacokinetics an ...... infected infants and children.

@en

Population pharmacokinetics an ...... infected infants and children.

@nl

prefLabel

Population pharmacokinetics an ...... infected infants and children.

@en

Population pharmacokinetics an ...... infected infants and children.

@nl

P1433

Q44343579-5DD3C477-20A2-45F5-958D-B96CB8B9A436

P1476

Q44343579-0B201ACF-DCF1-470D-9D6B-D1AE61234270

P2093

Q44343579-00CB22B0-3BFA-4CAC-8C43-3B46B03A8977

Q44343579-73B90EBF-5CC5-4592-92FD-7A793D07B461

Q44343579-7605DFF4-8E65-497A-B211-5849A93E2B85

Q44343579-8CBB98D6-674A-4E41-B2D6-E38F1826370A

Q44343579-B9C686A0-1F2A-4B74-9EBE-54CF889E8F57

Q44343579-D90C09F2-3E43-4A2B-AD37-328AECA3CDDE

Q44343579-DE9FEA82-6960-49A0-AE86-E4D76581C07C

P2860

Q44343579-04E09DA4-56CA-4393-A479-6B2DF991B293

Q44343579-04F977CB-0F2D-4DF7-BD57-B6D693D432AC

Q44343579-2278046D-A40A-42A4-902E-C6706CCA4582

Q44343579-337C52EA-7D78-4C92-81CD-ACD3D1441649

Q44343579-3F1C798A-C7DD-4F45-B490-38CE366E0921

Q44343579-58DB843B-9D50-49B3-B480-F8C7DAE3FF23

Q44343579-76D2480F-9F9D-4D6B-91B1-A15FA02EA1F8

Q44343579-817B944E-0D2E-4189-822D-131735F7AE65

Q44343579-97215C47-B6B8-4658-A617-C0A50C82EBE5

Q44343579-A737DEFC-FC9F-4ECB-BF45-5650834A1D4D

P304

Q44343579-98B2F0AD-61B8-445F-ACD3-1AAABDF3AC52

P31

Q44343579-C728D37D-D2B2-411F-B6AB-418B7B0ACE0D

P356

Q44343579-E4471F47-4C6A-4B1E-9BB7-E48E4EEB9C48

P433

Q44343579-2D5DBB71-C4B9-46E2-B52E-99608D4927FE

P478

Q44343579-668FAC31-C080-477D-A242-A436BB641BDD

P577

Q44343579-B2593B71-C6F6-4156-821F-82B6EEC71675

P698

Q44343579-4F53E452-E1A4-4634-9851-2E8C70B08BBD

P356

0091270002239821

P1433

The Journal of Clinical Pharmacology

P1476

Population pharmacokinetics an ...... infected infants and children.

@en

P2093

Carol J Baker

http://www.w3.org/2001/XMLSchema#string

Edmund V Capparelli

http://www.w3.org/2001/XMLSchema#string

James D Connor

http://www.w3.org/2001/XMLSchema#string

Janet A Englund

http://www.w3.org/2001/XMLSchema#string

Paul Palumbo

http://www.w3.org/2001/XMLSchema#string

Ross E McKinney

http://www.w3.org/2001/XMLSchema#string

Stephen A Spector

http://www.w3.org/2001/XMLSchema#string

P2860

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

A general model for the origin of allometric scaling laws in biology

Quantitative relationships between zidovudine exposure and efficacy and toxicity

Clinical pharmacokinetics of zidovudine. An update.

Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus.

Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.

Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity.

Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group.

Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children.

Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring.

P304

133-140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270002239821

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12616665

http://www.w3.org/2001/XMLSchema#string